Molecular Devices
Founded Year
1983Stage
Acquired | AcquiredTotal Raised
$50KAbout Molecular Devices
Molecular Devices develops bio-analytical measurement systems. It offers microplate readers, cellular imaging systems, clone screening and more products. The company integrates its expertise in engineering, molecular, cell biology and chemistry. Molecular Devices was founded in 1983 and is based in San Jose, California.
Missing: Molecular Devices's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Molecular Devices's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Molecular Devices Patents
Molecular Devices has filed 112 patents.
The 3 most popular patent topics include:
- Microscopy
- Cell biology
- Optical devices
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
6/3/2019 | 12/6/2022 | Microscopy, Transiting exoplanets, Digital photography, Image sensors, Microscopes | Grant |
Application Date | 6/3/2019 |
|---|---|
Grant Date | 12/6/2022 |
Title | |
Related Topics | Microscopy, Transiting exoplanets, Digital photography, Image sensors, Microscopes |
Status | Grant |
Latest Molecular Devices News
Oct 10, 2022
Eröffnung der Standorterweiterung in Puch/Hallein und Präsentation des „Organoid Innovation Center – Salzburg“ Salzburg/Puch Urstein (OTS) - "Molecular Devices“ ist einer der weltweit führenden Anbieter bioanalytischer Lösungen für die Protein- und Zellbiologie in der Life-Science-Forschung, der pharmazeutischen und biotherapeutischen Entwicklung. Mit Hauptsitz in Silicon Valley, Kalifornien, hat "Molecular Devices“ zudem Niederlassungen in Großbritannien, Deutschland, Korea, China, Japan, Indien und in Österreich - dem neuen Zentrum der globalen Forschung und Entwicklung. Drei Jahre nach der Standorteröffnung von Molecular Devices Austria in Puch bei Hallein feiert das innovative Unternehmen den erfolgreich abgeschlossenen Ausbau des Organoid Innovation Center – Salzburg. Wir möchten Ihnen - veranschaulicht mit einer spannenden Besichtigungstour durch die Welt der 3D Biotechnologie - zeigen, welche High-Tech Produkte hier entstehen, was genau sich hinter „Organoid-Innovation“ verbirgt, warum gerade Österreich neben Silicon Valley als zweites Organoid Innovation Center und globales R&D Center weltweit gewählt wurde und vieles mehr. Anlässlich der Eröffnung laden wir Medienvertreter:Innen herzlich zu einer Pressekonferenz und einer Besichtigungs-Tour durch die Welt der 3-D-Biologie. Datum: Mittwoch, 12. Oktober 2022 Zeit: 10:30 Besichtigungs-Tour durch die Welt der 3-D-Biologie, 12:00 Beginn Pressekonferenz Ort: Wissenspark Salzburg Urstein, Urstein Süd 17, Puch bei Hallein (Parkplätze in der Tiefgarage) Susan Murphy (President Molecular Devices, LLC/San Jose, Kalifornien) Wilfried Haslauer (Landeshauptmann Salzburg) Helmut Klose (Bürgermeister Gemeinde Puch) Die Pressekonferenz findet hybrid statt. Sie können persönlich teilnehmen, oder auch online die Pressekonferenz ab 12:00 verfolgen. Aus organisatorischen Gründen ersuchen wir um Ihre Anmeldung unter office@freecomm.cc oder telefonisch unter +43 676 / 624 17 85. Danke! Hybrid-Pressekonferenz von Molecular Devices Austria in Puch Drei Jahre nach der Standorteröffnung von Molecular Devices Austria in Puch bei Hallein feiert das innovative Unternehmen am 12. Oktober 2022 den erfolgreich abgeschlossenen Ausbau des Organoid Innovation Center – Salzburg. Molecular Devices ist einer der weltweit führenden Anbieter bioanalytischer Lösungen für die Protein- und Zellbiologie in der Life-Science-Forschung, der pharmazeutischen und biotherapeutischen Entwicklung. Datum: 12.10.2022, 10:30 - 12:30 Uhr Ort: Wissenspark Salzburg Urstein, Urstein Süd 17, Puch bei Hallein Puch bei Hallein, Österreich
Molecular Devices Frequently Asked Questions (FAQ)
When was Molecular Devices founded?
Molecular Devices was founded in 1983.
Where is Molecular Devices's headquarters?
Molecular Devices's headquarters is located at 3860 N First Street, San Jose.
What is Molecular Devices's latest funding round?
Molecular Devices's latest funding round is Acquired.
How much did Molecular Devices raise?
Molecular Devices raised a total of $50K.
Who are the investors of Molecular Devices?
Investors of Molecular Devices include MDS Pharma Services and Sutter Hill Ventures.
Who are Molecular Devices's competitors?
Competitors of Molecular Devices include CellChorus.
Compare Molecular Devices to Competitors
Spatial Genomics is a biology and life science technology company dedicated to empowering discovery. Spatial Genomics’ integrated technology platform consists of instrumentation, reagents, and software and is being developed with a vision of providing high multiplexity of multi-omic biological analysis capabilities. Its highly multiplexed spatial analysis technology will advance fundamental biology, precision medicine, drug, and biomarker discovery.
Singleron is a developer of gene sequencing technology, focusing on massive and single-cell multi-omics analysis for drug development, scientific research, and genomics industries. The company develops a series of molecular diagnostic products and automation devices that can meet clinical applications.
Mission Bio is developing technologies to analyze single cells within complex biological systems, revealing critical information not observable from bulk sample analysis. With proprietary microfluidic droplet technology, Mission Bio is developing research tools that allow high-throughput, single-cell nucleic acid characterization across a variety of research applications, including oncology and immunology.
Celsius Therapeutics applies a systematic approach to single-cell sequencing, combining massive datasets and complex algorithms in order to discover precision therapies that have an impact on the lives of patients with autoimmune diseases and cancer. By analyzing single cells, Celsius's approach has the potential to understand the causes of disease at an entirely new level of resolution that overcomes limitations of traditional genomic sequencing approaches.
CytoTronics enables optics-free imaging for drug discovery through its complementary metal-oxide-semiconductor (CMOS) electronics platform. Its technology measures and manipulates live cells to produce high-resolution electrical and electrochemical cell-based assays. By providing single-cell resolution readouts, CytoTronics help enhance the accuracy of cell-biology information. The company was founded in 2020 and is based in Boston, Massachusetts.
Vizgen is developing the next generation of spatially resolved genomic profiling tools that enable researchers to gain new insight into the biological systems that underlie human health and disease. The company's patented MERFISH technology enables massively multiplexed, genome-scale nucleic acid imaging with high accuracy and detection efficiency at subcellular resolution. MERFISH provides transformative insight into a wide range of tissue-scale basic research and translational medicine in oncology, immunology, neuroscience, infectious disease, developmental biology, and regenerative medicine. The company was founded in 2019 and is based in Cambridge, Massachusetts.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.